| ThinkEquity Initiates Coverage of Annovis Bio (NYSE American: ANVS) with Buy Rating and $20 PT |
| |
|
ThinkEquity initiated coverage of Annovis Bio (NYSE American: ANVS) with a buy rating and $20 price target.
Annovis Bio is a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. Its lead drug candidate, ANVS401, improves axonal transport or the information pathway of the nerve cell. ANVS401 attacks multiple neurotoxic proteins simultaneously, improves axonal transport, and impedes the toxic cascade.
The company estimates the potential annual worldwide market size for a disease-modifying treatment in neurodegenerative diseases is over $100 billion. Based on a discounted cash flow analysis of the projected free cash flows of ANVS401, ThinkEquity estimates sales of $100 million for ANVS401, across all indications, in the U.S. by 2024. Contributions from geographies outside the U.S were excluded. The company forecast sales of about $2 billion, in AD and PD, for ANVS401 in 2025 and $10 billion in 2026.
Based on these assumptions, and applying a 30% discount rate, the discounted cash flow analysis indicated an estimated value per share of $18 for ANVS. ThinkEquty’s price target of $20 is supported by DCF sum-of-the-parts valuation and $2 in estimated net cash/share.
View Full Report
ThinkEquity: Annovis Bio - Research Report
Disclosure
Annovis (ANVS) is a client of RedChip Companies, Inc. ANVS agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in February 2020, for RedChip investor awareness services and consulting services.
|
|
| |
|
| CytoDyn (OTCQB: CYDY) Collaborates with Mexican National Institutes of Health on Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Patients |
| |
|
CytoDyn (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, will be coordinating with the NIH of Mexico and providing leronlimab for a trial for the severe/critical COVID-19 population in Mexico with the potential to collaborate on further CytoDyn COVID-19 trials.
Why It Matters: CytoDyn is currently enrolling a Phase 2b/3 clinical trial for 390 patients, which is a randomized, placebo-controlled with 2:1 ratio (active drug to placebo ratio). CytoDyn is also enrolling a Phase 2 randomized clinical trial with 75 patients in the mild-to-moderate COVID-19 population. CytoDyn has been granted more than sixty emergency Investigational New Drug (eIND) authorizations by the U.S. Food and Drug Administration (FDA) and plans to provide clinical updates for this patient population later in the week.
Key Quote: “We look forward to working with the NIH of Mexico to rapidly commence with the proposed study. We also believe that this study results, along with the ongoing Phase 2 study, could establish a path for quick approval in Mexico for use of leronlimab in COVID-19 patients.” - Nader Pourhassan, Ph.D., CEO
The Backstory: CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
Disclosure
CytoDyn (CYDY) is a client of RedChip Companies, Inc. CYDY agreed to pay RedChip Companies, Inc., a $20,000 quarterly cash fee, beginning in February 2020, for RedChip investor awareness services.
|
|
| |
|
| Esports Entertainment Group (NASDAQ: GMBL) Begins Onboarding Hundreds of Affiliate Partners to Newly Relaunched VIE.gg Esports Betting Platform |
| |
|
Esports Entertainment Group (NASDAQ: GMBL), a licensed online gambling company with a focus on esports wagering and 18+ gaming, has officially begun onboarding hundreds of affiliate marketing partners to its newly relaunched VIE.gg wagering platform. The affiliate partners include esports teams, influencers, streamers, leagues, and super affiliates from Asia, Europe, North America and South America. The Company believes its Affiliate Marketing program will play a significant role in its organic growth.
Why it Matters: The Company’s recently announced Malta gaming license and recent listing on NASDAQ are cited by our affiliate partners as very strong factors in their decision to partner with VIE.gg. Though the Company first began registering a small sample of interested affiliates in 2018, these two factors have generated noticeable enthusiasm from existing and new affiliates who take great comfort in knowing the Company is working within one of the strictest licensing and listing regulatory environments, as compared to private operators. Moreover, the Company’s financial strength as a result of its successful $8.4million public offering now provides VIE.gg with the resources necessary to support and grow its soon to be large affiliate partner base.
Key Quote: “Our Affiliate partners are a very important part of our organic growth strategy in 2020 and beyond, so it has been a high priority of ours to provide the comfort and security they need to partner with us and drive their valuable global audiences to VIE.gg.” - Grant Johnson, CEO
The Backstory: Esports Entertainment Group is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fantasy, pools, fixed odds and exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at vie.gg. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in Curacao, Kingdom of the Netherlands.
Disclosure
Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a $4,000 monthly cash fee, beginning in June 2018, and 225,000 shares of Rule 144 stock for RedChip investor awareness services.
|
|
| |
|
| Milestone Scientific (NYSE American: MLSS) Provides Business Update for Q1 of 2020 |
| |
|
Milestone Scientific (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, provided a business update and announced financial results for the first quarter ended March 31, 2020.
Key Quote: “We continue to witness a growing interest in the CompuFlo® CathCheck™ System, which is now in a pilot at a leading medical institution in the United States. Had it not been for COVID-19 and the fact that hospitals are on complete lockdown, we believe we would have already announced several important commercial agreements. Nevertheless, once the current pandemic begins to subside, we believe we will be well positioned coming out of the gate.” – Len Osser, interim-CEO
The Backstory: Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.
Disclosure
Milestone Scientific (MLSS) is a client of RedChip Companies, Inc. MLSS agreed to pay RedChip Companies, Inc. 18,000 shares of Rule 144 stock for three months of RedChip investor awareness services and consulting services, beginning April 2020.
|
|
| |
|
| Can-Fite BioPharma (NYSE American: CANF) Reports Additional Findings from Successful Phase II NASH Study |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH).
Why It Matters: On April 7, the Company reported topline results from the Phase II study indicating Namodenoson had achieved its efficacy endpoints in a dose dependent and statistically significant manner, while continuing to demonstrate a good safety profile. Most significantly, a more recent in-depth review of the Phase II data reveal 25 mg of Namodenoson was found to resolve significantly all cases of NASH, representing 25% of the 25 mg treated group, as compared to an increase in new NASH cases in the placebo group from a baseline of 0 to 5.9%. In the Phase II study, 25 mg of Namodenoson was shown to reduce hepatic fibrosis (scar tissue in the liver resulting from the liver trying to repair itself), reduce steatosis (fat buildup in the liver), and improve the FAST score, a measure for NASH (liver stiffness and an enzymatic biomarker of liver damage).
Key Quote: “The data show that Namodenoson reversed and eliminated NASH, and may prevent the progression of NAFLD into NASH. We are very pleased and impressed by these results. Given the clear need for approved drugs in this indication, we believe Namodenoson is a strong candidate for advanced stage clinical development as a treatment for both NAFLD and NASH.” – Rifaat Safadi, Principal Investigator
The Backstory: Can-Fite is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Piclidenoson has been approved for a pilot clinical trial in Israel to treat COVID-19 infected patients with moderate-to-severe symptoms. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL) Completes Additional Testwork to Produce High Grade Spodumene and Byproduct Concentrates |
| |
|
Piedmont Lithium (NASDAQ: PLL) announced that it has produced 120 kg of spodumene concentrate from core samples collected from the Company’s Piedmont Lithium Project located within the world-class Carolina Tin-Spodumene Belt.
Why It Matters: The core samples have now been used in the bench-scale lithium hydroxide testwork program nearing completion at SGS laboratories in Lakefield, Ontario. Concentrate qualities and recoveries were consistent with earlier testwork programs. The updated spodumene concentrate and byproduct results will be used to support the Company’s study updates which will be announced later this month.
Key Quote: “Our lithium hydroxide testwork program continues at SGS, and is based on the high-quality, low impurity spodumene concentrate prepared from a 1.75 tonne representative ore sample from Piedmont’s Core property. Byproduct testwork is also continuing, and after positive initial customer feedback we have received from prospective quartz customers, we are beginning to evaluate the opportunity to expand our planned byproduct production, potentially further lowering our spodumene concentrate costs.” – Keith Philliips, President
Backstory: Location is one of the standout features of the Piedmont project, with access to excellent infrastructure and transport options, close proximity to existing lithium chemical processing facilities operated by Livent (NYSE: LTHM) and Albemarle (NYSE: ALB), and within reach of 13 auto manufacturing facilities. Compared to Australian- and Canadian-based projects, North Carolina offers a significantly lower-cost operating environment (labor, power/gas/diesel, transport), which is further boosted by the absence of government royalties and a low tax rate environment. Lithium is on the US Government’s Critical Minerals list, giving the project significant strategic value as being the only conventional US lithium development project.
Disclosure
Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a quarterly cash fee of $20,000, beginning in April 2019, for 12 months of RedChip investor awareness services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Provides Update on 1606 Hemp Direct to Store Sales Strategy |
| |
|
SinglePoint (OTCQB: SING) recently launched a new strategic direct to store (DSD) sales initiative focused on initial product placement and market penetration within convenience stores and smoke shops in the domestic US market for its 1606 Hemp cigarettes. This DSD strategy is designed to enhance sales, initial product placement and augment existing traditional retail distribution sales efforts leveraging the recent introduction of the new countertop displays.
Why It Matters: SinglePoint (OTCQB: SING) recently launched a new strategic direct to store (DSD) sales initiative focused on initial product placement and market penetration within convenience stores and smoke shops in the domestic US market for its 1606 Hemp cigarettes. This DSD strategy is designed to enhance sales, initial product placement and augment existing traditional retail distribution sales efforts leveraging the recent introduction of the new countertop displays.
Backstory: 1606 Hemp was designed to be the premium brand in the combustible hemp market which is the second fastest growing market in the hemp category. 1606 Hemp continues to innovate and differentiate itself as evidenced by the recent introduction of a six pack point of sale display unit designed to be placed on countertops or next to the register retail locations across the nation. Our filtered pre-rolls are made from broad spectrum American grown, harvested and cured hemp flower. Less than 0.3% THC and nearly 20% CBD in each pre-roll, they provide a smooth alternative to tobacco products. We use sustainable farming techniques, biodegradable filters and third party tests for quality, compliance and safety.
Disclosure
SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2019, for RedChip investor awareness services and consulting services.
|
|
| |
|
| |
| Quote of the Week |
| |
"There are exceptions and dumb luck, but you have to be savvy in this space."
- Greg Sichenzia, Founding Partner Sichenzia Ross Friedman Ference |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
